Zobrazeno 1 - 10
of 29
pro vyhledávání: '"anti-helicobacter pylori therapy"'
Autor:
E. V. Golubkina
Publikováno v:
Антибиотики и Химиотерапия, Vol 68, Iss 0, Pp 4-48 (2023)
Background. Chronic gastritides still have no division into forms according to the data of the genotyping of Helicobacter pylori isolates. Monitoring the results of anti-Helicobacter pylori therapy cannot be limited to eradication, by taking into acc
Externí odkaz:
https://doaj.org/article/d92abcb8b49f4af4b401af81501ea06f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
I. G. Bakulin, N. V. Bakulinа, S. L. Vorobyov, E. A. Popova, O. A. Malikhova, P. A. Zeynalova, T. A. Ilchishina, V. V. Lozovaya, F. M. Abbasbeyli
Publikováno v:
Онкогематология, Vol 14, Iss 3, Pp 23-37 (2019)
Due to the pronounced polymorphism of stomach MALT-lymphoma endoscopic manifestations, often mimicking inflammatory changes of various etiologies, difficulties arise in the timely diagnosis of this disease. The alertness of the endoscopist and the us
Externí odkaz:
https://doaj.org/article/c18f6687ccf54abba823bc3192aa6778
Autor:
E. Y. Plotnikova, T. Y. Gracheva
Publikováno v:
Медицинский совет, Vol 0, Iss 5, Pp 80-84 (2017)
Helicobacter pylori (Hp) is a widespread gram-negative, spiral microorganism with flagella that infects the stomach lining. In 1994, the International Agency for Research on Cancer included H. pylori in the list of group 1 carcinogens. Therapeutic op
Externí odkaz:
https://doaj.org/article/05798606a72649039dfa943e07c6be71
Publikováno v:
Journal of Education, Health and Sport, Vol 6, Iss 6, Pp 619-628 (2016)
Shuhtina I. N., Petrenko A. A., Uspensky O. E., Gozhenko A. I. Развитие дисбиоза и воспаления в организме крыс, получавших антихеликобактерную терапию и их профила
Externí odkaz:
https://doaj.org/article/c680992d95654266af44fc19c0e59e86
Publikováno v:
Терапевтический архив, Vol 88, Iss 4, Pp 75-81 (2016)
Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A pros
Externí odkaz:
https://doaj.org/article/6ebba4cee6dc49899868fa5ccff77a9b
Publikováno v:
Архивъ внутренней медицины, Vol 6, Iss 1, Pp 29-33 (2016)
The article presents the results of a prospective clinical study in which 100 patients with H. pylori-associated peptic ulcer disease of stomach/duodenum were examined. The aim of the study was to assess the effect of concomitant anamnestic and clini
Externí odkaz:
https://doaj.org/article/1f4853bf9eb24a19be506c1ff26a8cb1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
I. N. Shuhtina, A. A. Petrenko, O. E. Uspensky, A. I. Gozhenko, V. V. Shuhtin, L. M. Bobrik, R. N. Boris
Publikováno v:
Journal of Education, Health and Sport, Vol 5, Iss 11, Pp 227-237 (2015)
Shuhtina I. N., Petrenko A. A., Uspensky O. E., Gozhenko A. I., Shuhtin V. V., Bobrik L. M., Boris R. N. Развитие дисбиоза и воспаления в организме крыс, получавших антихеликобактерн
Externí odkaz:
https://doaj.org/article/934c077381124632834bed9a4d22db10
Autor:
Chih-Ming Liang, Jen-Wen Cheng, Chung-Mou Kuo, Kuo-Chin Chang, Keng-Liang Wu, Wei-Chen Tai, King-Wah Chiu, Shue-Shian Chiou, Ming-Tsung Lin, Tsung-Hui Hu, Seng-Kee Chuah
Publikováno v:
Biomedical Journal, Vol 37, Iss 5, Pp 326-330 (2014)
Background: Quinolone-containing triple therapy is recommended as an option for non-bismuth containing second-line Helicobacter pylori eradication. Current available Taiwanese reports in the literature used 7-day quinolone-containing triple therapy.
Externí odkaz:
https://doaj.org/article/5d3beeb763ae4fb7b814d8a7113a985a